Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74

Benzinga · 2d ago
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.